We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

127 hedge funds and large institutions have $88.4M invested in Arbutus Biopharma in 2022 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 45 increasing their positions, 33 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 5

56% more call options, than puts

Call options by funds: $1.95M | Put options by funds: $1.25M

36% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 33

12% more funds holding

Funds holding: 113 → 127 (+14)

1.29% more ownership

Funds ownership: 29.8% → 31.09% (+1.3%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

26% less capital invested

Capital invested by funds: $119M → $88.4M (-$30.7M)

Holders
127
Holders Change
+14
Holders Change %
+12.39%
% of All Funds
2.19%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
20
Increased
45
Reduced
33
Closed
5
Calls
$1.95M
Puts
$1.25M
Net Calls
+$696K
Net Calls Change
-$1.48M

Top Buyers

1
TSC
Two Seas Capital
New York
+$5.07M
2
OMC
Oasis Management Company
Cayman Islands
+$2.42M
3
Marshall Wace
Marshall Wace
United Kingdom
+$925K
4
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$691K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$529K

Top Sellers

1
BC
Brookfield Corp
Ontario, Canada
-$5.19M
2
Millennium Management
Millennium Management
New York
-$1.53M
3
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$533K
4
Simplex Trading
Simplex Trading
Illinois
-$209K
5
Goldman Sachs
Goldman Sachs
New York
-$189K
Name Holding Trade Value Shares
Change 		Change in
Stake
KC
26
Kepos Capital
New York
$382K – – –
Citadel Advisors
27
Citadel Advisors
Florida
$358K +$248K +105,406 +128%
Fidelity Investments
28
Fidelity Investments
Massachusetts
$357K +$55.3K +23,469 +14%
Jacobs Levy Equity Management
29
Jacobs Levy Equity Management
New Jersey
$351K +$433K +183,867 New
RhumbLine Advisers
30
RhumbLine Advisers
Massachusetts
$273K +$18.6K +7,916 +6%
Ameriprise
31
Ameriprise
Minnesota
$260K +$69K +29,300 +27%
GCP
32
GSA Capital Partners
United Kingdom
$181K +$185K +78,664 +488%
Royal Bank of Canada
33
Royal Bank of Canada
Ontario, Canada
$177K -$71.6K -30,426 -25%
Connor, Clark & Lunn Investment Management (CC&L)
34
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$173K +$213K +90,497 New
Man Group
35
Man Group
United Kingdom
$167K +$205K +87,246 New
AA
36
ALPS Advisors
Colorado
$156K -$14.9K -6,346 -7%
New York State Common Retirement Fund
37
New York State Common Retirement Fund
New York
$144K +$810 +344 +0.5%
JP Morgan Chase
38
JP Morgan Chase
New York
$133K +$13K +5,543 +9%
PI
39
PEAK6 Investments
Illinois
$119K +$147K +62,400 New
MIM
40
MetLife Investment Management
New Jersey
$112K +$54.9K +23,312 +66%
Bank of America
41
Bank of America
North Carolina
$105K +$39.4K +16,728 +43%
Rafferty Asset Management
42
Rafferty Asset Management
New York
$104K -$31.6K -13,407 -20%
PCM
43
Prelude Capital Management
New York
$103K -$34.6K -14,688 -21%
LP
44
LMR Partners
United Kingdom
$103K – – –
AIG
45
American International Group
New York
$98K +$1.71K +725 +1%
Deutsche Bank
46
Deutsche Bank
Germany
$94K -$17K -7,217 -13%
Renaissance Technologies
47
Renaissance Technologies
New York
$87K +$107K +45,660 New
EMG
48
ETF Managers Group
New Jersey
$85K -$6.45K -2,738 -6%
VEA
49
Virtus ETF Advisers
New York
$82K +$737 +313 +0.7%
California State Teachers Retirement System (CalSTRS)
50
California State Teachers Retirement System (CalSTRS)
California
$81K -$8.37K -3,554 -8%
1
2
3 4 5

ABUS Hedge Fund Activity: Q3 2022 in Review

127 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2022, worth a combined $88.4M — down 26% from $119M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new ABUS positions and 5 closed out — a net gain of 15 holders — while 45 added to existing stakes and 33 trimmed.

The largest buyer was Two Seas Capital, adding an estimated $5.07M. The largest seller was Brookfield Corp, exiting entirely with an estimated $5.19M sold.

  • 127 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2022, up from 113 in Q2 2022.
  • Funds reported $88.4M of Arbutus Biopharma stock for Q3 2022, down 26% quarter-over-quarter.
  • 20 funds opened new Arbutus Biopharma positions in Q3 2022 and 5 closed out, a net change of +15 holders.
  • The largest Arbutus Biopharma buyer in Q3 2022 was Two Seas Capital, an estimated $5.07M added.
  • The largest Arbutus Biopharma seller in Q3 2022 was Brookfield Corp, an estimated $5.19M sold.

Based on aggregated 13F filings for Q3 2022.